- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sterling reaches deal with OIS for TFT supply
Sterling reaches deal with OIS for TFT supplySterling Diagnostic Imaging has reached a settlement with Optical Imaging Systems that will enable the Greenville, SC-based Sterling to gain access to all of the thin-film transistor (TFT) arrays at
Sterling reaches deal with OIS for TFT supply
Sterling Diagnostic Imaging has reached a settlement with Optical Imaging Systems that will enable the Greenville, SC-based Sterling to gain access to all of the thin-film transistor (TFT) arrays at OIS. OIS announced that it had shut its doors when its primary investor withdrew its funding (
PNN
10/98).
Sterling will also receive the work-in-progress arrays at OIS, according to Sterling. The agreement assures the company of an allocated supply of iiRad systems with DirectRay into the second quarter of 1999, said Ernest Waaser, COO.
Meanwhile, Sterling is having encouraging discussions with several alternative TFT suppliers that could result in resumed production of TFT panels for Sterling by mid-1999, he said. This would result in minimal impact on supply of iiRad with DirectRay systems, he said. n
- Search again
- Homepage
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
